Cipla vs Metropolis Healthcare Q4 FY26

CI

Cipla

Q4 FY26 · Healthcare

Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M. The company achieved key milestones including generic Ventolin approval and crossing 12,500 Cr in India revenue. Management guided for FY27 EBITDA margins of 18.5-20% with sequential improvement, driven by US respiratory launches and India chronic portfolio expansion. The US business targets a $1B run-rate by FY27-end, supported by 4 respiratory approvals and a peptide launch. Key risk: geopolitical disruptions and war-related cost inflation could pressure near-term margins.

Guidance read

FY27 EBITDA margin guidance of 18.5-20%: Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2. US business to reach $1B run-rate by FY27-end: Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches. India business to deliver double-digit growth in FY27-28: Management expects strong double-digit and market-beating growth in India for FY27 and FY28. R&D spend to remain around 7% of sales: R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.

Risk read

Key risks include Geopolitical disruption and war-related cost inflation — Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.; Lanreotide supply disruption and remediation uncertainty — Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.; Indore facility regulatory overhang — Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.; Execution risk in US respiratory launches — Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%. Organic revenue grew 13.7% YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5% and realization improvement. Organic EBITDA margin expanded 140 bps to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.

Guidance read

Organic revenue growth of 14-15% over next 3 years: Driven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases. Group EBITDA margin target of 27-28% over next 3 years: Supported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin. 125-150 bps margin improvement in FY27: Management expects EBITDA margin expansion of 125-150 bps in the coming fiscal year. Add 1500 collection centers and 100 mini hubs over 3 years: Expand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.

Risk read

Key risks include Competitive intensity in tier-1 cities — Growth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.; Integration risks from future M&A — While current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.; Dependence on price increases for growth — Management indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist..

Promise ledger

Scorecard data is being built as historical quarters are processed.